Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $74M (up 37.1% year over year) with net income of $621,000.
Q3 2025 key financials · XBRL
- Revenue
- $74M
- +37.1% YoY · +4.0% QoQ
- Net income
- $621,000
- +103.9% YoY · +132.2% QoQ
- Operating margin
- 9.0%
- EPS (diluted)
- $0.00
- +100.0% YoY · +100.0% QoQ
Source: XBRL data from the Xeris Biopharma Holdings, Inc. (XERS) Q3 2025 10-Q on SEC EDGAR. USD.
Xeris Biopharma Holdings, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Investing cash used $363.0K, down from $5.1M YoY, reflecting fewer short-term investment purchases
- Financing cash provided $11.7M, down from $35.8M YoY
- Stock awards and warrant settlements generated $20.2M; tax-related share repurchases used $9.3M
Risk Factors
- No material changes to risk factors since December 31, 2024 Form 10-K
- Carried-forward risks could materially affect business operations and consolidated financial statements
- Additional unknown or currently immaterial risks could impair operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Xeris Biopharma Holdings, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.